ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

PHASE4CompletedINTERVENTIONAL

Enrollment

3,045

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 8, 2018

Study Completion Date

December 31, 2023

Conditions

Coronary Artery Disease

Interventions

DRUG

1-month DAPT

1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists

DRUG

12-month DAPT

12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists

Trial Locations (1)

Division of Cardiology, Kyoto University Hospital, Kyoto

All Listed Sponsors

lead

Kyoto University, Graduate School of Medicine

OTHER

NCT02619760 - ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study | Biotech Hunter | Biotech Hunter